Somavert® (pegvisomant)

SOMAVERT® (pegvisomant) can be prescribed in adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues (SSAs) did not normalise IGF-I concentrations or was not tolerated.3

 

 

References:

1- Melmed S, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth facto-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicentre study with a 52 week open extension. Pituitary 2010; 13: 18-28.

2- Colao A, et al. Pasireotide vs. Octreotide in Acromegaly: A Head-to-Head Superiority Study. J Clin Endocrinol Metab 2014; 99(3):791-799.

3- Summary of Product Characteristics- Somavert. March 2019 (Accessed on www.medicines.org.uk/emc/product/64 )

PP-SOM-GBR-0327. April 2019